Openbookopenbook
Equity
Niagen Bioscience, Inc.(NAGE)
USD --+0.00%
Reward70High
Risk35Moderate
📊75%Data
Strong 16% profit margin · Revenue growing 33% YoY
NAGE
+0.0 · +0.00%
USD · NASDAQ
Niagen Bioscience, Inc. | Healthcare
Quality Compounder
Market Cap:425.37M
ℹ️
Reward Rating
70
High
Top 25% (model universe)
75% data coverage
ℹ️
Risk Rating
35
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on NAGE to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $15.80.

What is Niagen Bioscience, Inc.?

operates as a bioscience company engages in developing healthy aging products.

NAGE · Verdict

Strong reward · moderate risk

NAGE stands out on balance sheet and profitability, but watch the volatility signal.

Based on 88% data coverage

NAGE · Verdict

What’s working & what to watch

Strengths 4

  • Balance sheet100/100

    Current ratio 3.57

  • Profitability85/100

    9% net margin · 39% ROE

  • Cash flow85/100

    12% free-cash-flow margin

  • Growth84/100

    Revenue +13.9% CAGR

Watchouts 2

  • Volatility5/100

    Weak vs peers

  • Valuation44/100

    P/E 28.4× · PEG 0.45

Model-based scoring. For information only — not financial advice.

What is Niagen Bioscience, Inc.?

operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 425.37M, and a P/E ratio of 22.2x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (70)

The scoring profile indicates a strong reward potential, driven primarily by profitability and growth. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap425.37M
P/E Ratio22.2083
Dividend YieldN/A
52 Week High14.69
52 Week Low4.74
Last AnnualDecember
IPO Date7/15/2008
IncorporatedUSA
Shares Outstanding80M
No. of Employees104
IndustryBiotechnology
ExchangeNASDAQ
Beta2.092
CurrencyUSD
Websitewww.niagenbioscience.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.